Clinical characteristics of responders to treatment with tolvaptan in patients with acute decompensated heart failure: Importance of preserved kidney size

Journal of Cardiology

Volumn 67, Issue 2, 2016, Pages 177-183

  Toda, Hironobu ^a,b   Nakamura, Kazufumi ^a   Nakahama, Makoto ^b   Wada, Tadashi ^a,b   Watanabe, Atsuyuki ^a,b   Hashimoto, Katsushi ^a,b   Terasaka, Ritsuko ^b   Tokioka, Koji ^a   Nishii, Nobuhiro ^a   Miyoshi, Toru ^a   Kohno, Kunihisa ^a   Kawai, Yusuke ^c   Miyaji, Kohei ^d   Koide, Yuji ^e   Tachibana, Motomi ^f   Yoshioka, Ryo ^g   Ito, Hiroshi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b Fukuyama City Hospital   (Japan)

^c EHIME PREFECTURAL CENTRAL HOSPITAL   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION OKAYAMA MEDICAL CENTER   (Japan)

^e Japan   (Japan)

^f SUWA RED CROSS HOSPITAL   (Japan)

^g THE SAKAKIBARA HEART INSTITUTE OF OKAYAMA   (Japan)

Author keywords

Heart failure; Kidney size; Vasopressin

Indexed keywords

TOLVAPTAN; BENZAZEPINE DERIVATIVE; VASOPRESSIN RECEPTOR ANTAGONIST;

ACUTE HEART FAILURE; AGED; ARTICLE; CLINICAL TRIAL (TOPIC); CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; JAPAN; KIDNEY SIZE; MALE; MULTICENTER STUDY (TOPIC); NEW YORK HEART ASSOCIATION CLASS; THORAX RADIOGRAPHY; TREATMENT RESPONSE; URINE OSMOLALITY; URINE VOLUME; ACUTE DISEASE; CLINICAL TRIAL; DRUG EFFECTS; HEART FAILURE; KIDNEY; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; ORGAN SIZE; OSMOLARITY; PATHOLOGY; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; URINE;

ACUTE DISEASE; AGED; ANTIDIURETIC HORMONE RECEPTOR ANTAGONISTS; BENZAZEPINES; FEMALE; GLOMERULAR FILTRATION RATE; HEART FAILURE; HUMANS; JAPAN; KIDNEY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ORGAN SIZE; OSMOLAR CONCENTRATION; PROSPECTIVE STUDIES;

EID: 84954322467     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2015.04.017     Document Type: Article

References (22)

1. JCS-Joint-Working-Group Guidelines for treatment of acute heart failure (JCS 2011). Circ J 2013, 77:2157-2201.
2. Gheorghiade M., Niazi I., Ouyang J., Czerwiec F., Kambayashi J., Zampino M., Orlandi C. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 2003, 107:2690-2696.
3. Gheorghiade M., Konstam M.A., Burnett J.C., Grinfeld L., Maggioni A.P., Swedberg K., Udelson J.E., Zannad F., Cook T., Ouyang J., Zimmer C., Orlandi C. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. J Am Med Assoc 2007, 297:1332-1343.
4. Inomata T., Izumi T., Matsuzaki M., Hori M., Hirayama A. Phase III clinical pharmacology study of tolvaptan. Cardiovasc Drugs Ther 2011, 25(Suppl. 1):S57-S65.
5. Watanabe K., Dohi K., Sugimoto T., Yamada T., Sato Y., Ichikawa K., Sugiura E., Kumagai N., Nakamori S., Nakajima H., Hoshino K., Machida H., Okamoto S., Onishi K., Nakamura M., et al. Short-term effects of low-dose tolvaptan on hemodynamic parameters in patients with chronic heart failure. J Cardiol 2012, 60:462-469.
6. Robertson G.L. Vaptans for the treatment of hyponatremia. Nat Rev Endocrinol 2011, 7:151-161.
7. Imamura T., Kinugawa K., Shiga T., Kato N., Muraoka H., Minatsuki S., Inaba T., Maki H., Hatano M., Yao A., Kyo S., Nagai R. Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patients - association between non-responders and chronic kidney disease. Circ J 2013, 77:397-404.
8. Imamura T., Kinugawa K., Minatsuki S., Muraoka H., Kato N., Inaba T., Maki H., Shiga T., Hatano M., Yao A., Kyo S., Komuro I. Urine osmolality estimated using urine urea nitrogen, sodium and creatinine can effectively predict response to tolvaptan in decompensated heart failure patients. Circ J 2013, 77:1208-1213.
9. Costello-Boerrigter L.C., Boerrigter G., Burnett J.C. Pharmacology of vasopressin antagonists. Heart Fail Rev 2009, 14:75-82.
10. Moghazi S., Jones E., Schroepple J., Arya K., McClellan W., Hennigar R.A., O'Neill W.C. Correlation of renal histopathology with sonographic findings. Kidney Int 2005, 67:1515-1520.
11. ACR-SPR Practice parameter for the performance of computed tomography (CT) of the abdomen and computed tomography (CT) of the pelvis. Res. 32-2011, Amended 2014 (Res. 39). Practice Parameters and Technical Standards 2014, American College of Radiology. http://www.acr.org/~/media/ACR/Documents/PGTS/guidelines/CT_Abdomen_Pelvis.pdf.
12. Toh N., Morita H., Nagase S., Taniguchi M., Miura D., Nishii N., Nakamura K., Ohe T., Kusano K.F., Ito H. Atrial electrophysiological and structural remodeling in high-risk patients with Brugada syndrome: assessment with electrophysiology and echocardiography. Heart Rhythm 2010, 7:218-224.
13. Japanese Society of Nephrology Evidence-based practice guideline for the treatment of CKD. Clin Exp Nephrol 2009, 13:537-566.
14. Giamouzis G., Sui X., Love T.E., Butler J., Young J.B., Ahmed A. A propensity-matched study of the association of cardiothoracic ratio with morbidity and mortality in chronic heart failure. Am J Cardiol 2008, 101:343-347.
15. Fukuta H., Ohte N., Brucks S., Carr J.J., Little W.C. Contribution of right-sided heart enlargement to cardiomegaly on chest roentgenogram in diastolic and systolic heart failure. Am J Cardiol 2007, 99:62-67.
16. Dupont M., Mullens W., Finucan M., Taylor D.O., Starling R.C., Tang W.H. Determinants of dynamic changes in serum creatinine in acute decompensated heart failure: the importance of blood pressure reduction during treatment. Eur J Heart Fail 2013, 15:433-440.
17. Matsue Y., Suzuki M., Seya M., Iwatsuka R., Mizukami A., Nagahori W., Ohno M., Matsumura A., Hashimoto Y. Tolvaptan reduces the risk of worsening renal function in patients with acute decompensated heart failure in high-risk population. J Cardiol 2013, 61:169-174.
18. Glodny B., Unterholzner V., Taferner B., Hofmann K.J., Rehder P., Strasak A., Petersen J. Normal kidney size and its influencing factors - a 64-slice MDCT study of 1.040 asymptomatic patients. BMC Urol 2009, 9:19.
19. Buchholz N.P., Abbas F., Biyabani S.R., Afzal M., Javed Q., Rizvi I., Talati J. Ultrasonographic renal size in individuals without known renal disease. J Pak Med Assoc 2000, 50:12-16.
20. Kojima K. CT of the kidney in chronic renal failure. J Okayama Med Assoc 2010, 100:857-872.
21. Lang C.C., Struthers A.D. Targeting the renin-angiotensin-aldosterone system in heart failure. Nat Rev Cardiol 2013, 10:125-134.
22. Nakamura K., Kusano K., Nakamura Y., Kakishita M., Ohta K., Nagase S., Yamamoto M., Miyaji K., Saito H., Morita H., Emori T., Matsubara H., Toyokuni S., Ohe T. Carvedilol decreases elevated oxidative stress in human failing myocardium. Circulation 2002, 105:2867-2871.